o2h ventures is an investment company that focuses on investing in smaller and unquoted companies in the human health sector. The company manages funds that invest in early-stage biotech and AI companies working on therapeutics or developing new ways to predict how drugs and the human body will behave.

o2h ventures

o2h Ventures is an established fund manager based in the heart of the biotech community in central Cambridge. We are a specialist fund that only invests in biotech therapeutics and the intersection between biotechnology and AI/ML. This fund is pivotal in developing the biotech ecosystem in the o2h Group but also has invested into 28 early-stage biotech companies in Great Britain. We have two specialist tax-efficient funds open for investment -  

1. The o2h human health SEIS Fund
2. The o2h human health EIS knowledge-intensive Fund

Disclaimer:

Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.

Your capital is at risk.  Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high-net-worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

o2h Ventures Ltd is a limited company registered in England and Wales under number 11397838 and is authorised and regulated by the Financial Conduct Authority (FRN 812245). The registered office and principal place of business is Hauxton House, Mill Scitech Park, Mill Lane, Hauxton, Cambridge, CB22 5HX, United Kingdom.

DeepMatter Group

o2h Ventures

We at o2h Ventures are looking for someone who knows the ins and outs of the UK's highly beneficial #EIS and #SEIS schemes—someone who is excited about educating others on the benefits of these schemes, empowering them, and building relationships in the industry.  
 
We are passionate about investing in early-stage biotech companies and are building a biotech ecosystem here in Cambridge, UK. So far, we have invested in 35 of the UK’s biotech companies; several of these have moved on further to raise significant capital from overseas and are building life-saving drugs/techs to benefit human health.
 
📌Apply here: https://lnkd.in/d8tDAujq or email us at invest@o2h.com 
 
Know someone perfect for this role? Mention or share with them in the comments!
 
#o2hVentures #UK #hiring #taxefficientfund #biotech

Check out some key figures for biotech financing in the latest report published by the BioIndustry Association (BIA):

🚀A remarkable 𝟭𝟯𝟱% 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 in funding from Q1 2024
📈The 𝗵𝗶𝗴𝗵𝗲𝘀𝘁-𝗲𝘃𝗲𝗿 quarterly raise since 2021
💡𝗥𝗶𝘀𝗲 in early-stage biotech deals: 15 in Q2 alone, compared to 28 in all of 2023

These figures highlight growing confidence among global investors and a well-positioned pipeline for the UK biotech sector. Explore more insights and detailed figures, here: https://lnkd.in/e94GgQWd

#o2hVentures #UK #biotech #investment

🎉 Thrilled to share that o2h Ventures has once again been named a Finalist in the 𝗕𝗲𝘀𝘁 𝗘𝗜𝗦 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 - 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 Category at the Growth Investor Awards 2024! 

This marks our third consecutive year qualifying for this prestigious award, and after being honoured as the runner-up last year, we are more driven than ever to continue our mission.

As a leading biotech specialist tax-efficient fund manager, we are deeply committed to fostering innovation and supporting early-stage biotech companies across the #UK. 

👏 Huge congratulations to all the incredible finalists! Check out the full list here: https://lnkd.in/d-gNCXH3  

#o2hVentures #biotech #eis #seis #awards

🎉 We are glad to announce our partnership for the 30th Anniversary EIS Celebration by the Enterprise Investment Scheme Association (EISA). 
 
The event celebrates three decades of the UK’s most innovative tax-efficient schemes, which aim to provide finance and nurture early-stage companies while providing attractive tax benefits to investors.
 
We look forward to the 18th of September to hear exciting panel discussions, network with our peers, and connect with founders, fund managers, investors, and the wider EIS/SEIS ecosystem. 
 
👉 Click here to learn more about the event, and get your ticket now: https://lnkd.in/db9Mnve6 
 
#o2hVentures #uk #eis #seis #network #events

🧑🔬“The UK  punches well above its weight, bringing in over 40% of all biotech investments across Europe as geography.  Despite these facts, there is a significant and well-understood valuation gap between the UK and other regions…” - Sunil Shah

What is happening within the UK biotech sector? Explore: 
- The truth about the UK biotech landscape
- Sunil Shah’s journey from consultant to biotech leader
- The valuation gap impacting the sector and more...

🔗 Click here to read the full article by the Life Science Nation - https://lnkd.in/g_8Jnvvi 

#o2h #seedingnewideas #biotech #lifescience #o2hVentures

Great to be a Podium Partner and looking forward to more collaborative rides in #Cambridge. 

#o2hVentures #seedingnewideas #biotechbikers #biotech

𝗠𝗮𝗿𝗸𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗠𝗼𝗻𝘁𝗵 𝘄𝗶𝘁𝗵 BiVictriX Therapeutics plc!  June is Cancer Immunotherapy Month, and we are thrilled to highlight one of our portfolio companies, BiVictriX Therapeutics (AIM: BVX), working towards developing safer and more effective treatments for #cancer therapies. Here are some of the key milestones they achieved this month!

✔ ️Secured £370K non-dilutive funding from Innovate UK to accelerate the development of their second therapeutic programme, BVX002, which targets ovarian cancer treatment. 
✔Their lead candidate, BVX001, aimed at treating Acute Myeloid Leukemia (AML), demonstrated a compelling safety profile in pre-clinical models. The toxicity results were favourable compared to FDA-approved Antibody Drug Candidates (ADCs), supporting progression to IND-enabling studies.

To learn more about the exciting work they are doing, please visit - https://bivictrix.com

#o2hVentures #eis #seis #portfolio #news #portfolionews

We are delighted to share that one of our portfolio companies, Oxford Drug Design, has secured grant funding to advance oncologic assets from the MRC (UK Medical Research Council) through their joint application with the Cancer Research UK (CRUK) Scotland Institute.
 
ODD is developing an innovative approach for the modulation of a validated cancer pathway fueling disease progression. The approach would be novel and have the potential to display improved efficacy and lower toxicity than existing treatments. The joint studies aim to combine the expertise of both parties and develop novel treatments with better efficacy for cancer. 
 
To learn more about this grant funding and Oxford Drug Design's groundbreaking work, please visit  - https://lnkd.in/dF6WMTz2
 
#o2hVentures #biotech #oncology #portfolio #news

👀Looking forward to OBN (UK) Ltd’s BioSeed event happening on 11 June, where three of our portfolio companies will be presenting. #BioSeed is OBN's flagship healthcare startup accelerator event, nurturing and showcasing cutting-edge innovations from our member companies. Here are the three o2h Ventures portfolio companies presenting:

- Stratosvir Limited is working to tackle the barriers to developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. 

- Clotprotect Tx is developing first-in-class small molecule CP101 which is a direct plasma inhibitor, which will help in improving the bleeding and survival outcomes compared to SOC to tranexamic acid. This has the potential to transform thrombosis management and save countless lives.

- CardiaTec Biosciences is at the forefront of cardiac care innovation with their AI-powered software that enables early detection and management of cardiovascular diseases, improving patient outcomes and quality of life.

Excited to see these innovative biotech companies showcased at BioSeed! 🚀

🚴🧬We had a cracking time last Saturday with our BiotechBikers! Over 30 enthusiastic biotech professionals joined us last Saturday for a scenic spin through the beautiful #Cambridge countryside. 
 
The event kicked off with a fascinating talk by Arpan titled "Sound Science: Lipid nanoparticles, #mRNA, and the future of hearing loss." This sparked lively discussions that flowed naturally, delving into hot topics like biotech investments with insights from local entrepreneurs and VCs. To fuel our post-ride energy, we enjoyed a delicious networking lunch where the conversation continued to buzz with ideas around all things biotech and biking.
 
👉If this sounds interesting for you, we'd love to welcome you to our next one! Simply reach out to us at invest@o2h.com, and we'll add you to the list.

#o2hVentures #biotech #biking

Metric
Company Name	o2h ventures
Symbol
MSH ID	COM:O2HVENTURES
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	UK
Stage
Employee Count
Website	o2hventures.com
LinkedIn	o2hventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

O2HV

COM:O2HVENTURES

o2h ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue